Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): Evasion of MRP-2 mediated efflux

International Journal of Pharmaceutics

Volumn 362, Issue 1-2, 2008, Pages 44-51

  Jain, Ritesh ^a   Agarwal, Sheetal ^a   Mandava, Nanda Kishore ^a   Sheng, Ye ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Effective intestinal permeability; Intestinal absorption; Multidrug resistance protein 2; Net water flux; Peff; Rat jejunum; Saquinavir; Single pass intestinal perfusion

Indexed keywords

DIPEPTIDE DERIVATIVE; GLYCYLVALINE SAQUINAVIR; MULTIDRUG RESISTANCE PROTEIN 2; PRODRUG; SAQUINAVIR; UNCLASSIFIED DRUG; VALYLVALINE SAQUINAVIR; VERLUKAST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; JEJUNUM; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HIV PROTEASE INHIBITORS; INTESTINAL ABSORPTION; JEJUNUM; MALE; PERFUSION; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SAQUINAVIR; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 50249154146     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.06.013     Document Type: Article

References (42)

1. Agarwal S., Pal D., and Mitra A.K. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int. J. Pharm 339 (2007) 139-147
2. Berggren S., Hoogstraate J., Fagerholm U., and Lennernas H. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci. 21 (2004) 553-560
3. Chiba M., Hensleigh M., and Lin J.H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem. Pharmacol. 53 (1997) 1187-1195
4. Crivori P., Reinach B., Pezzetta D., and Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol. Pharm. 3 (2006) 33-44
5. Cummins C.L., Salphati L., Reid M.J., and Benet L.Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 305 (2003) 306-314
6. Deeks S.G., Smith M., Holodniy M., and Kahn J.O. HIV-1 protease inhibitors. A review for clinicians. JAMA 277 (1997) 145-153
7. Dupre J., Behme M.T., Hramiak I.M., McFarlane P., Williamson M.P., Zabel P., and McDonald T.J. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44 (1995) 626-630
8. Fagerholm U., Johansson M., and Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13 (1996) 1336-1342
9. Fitzsimmons M.E., and Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25 (1997) 256-266
10. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338 (1998) 1281-1292
11. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5 (2004) 21-53
12. Huisman M.T., Smit J.W., Crommentuyn K.M., Zelcer N., Wiltshire H.R., Beijnen J.H., and Schinkel A.H. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids 16 (2002) 2295-2301
13. Issa C., Gupta P., and Bansal A.K. Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: a technical note. AAPS PharmSciTech 4 (2003) E16
14. Jain R., Agarwal S., Majumdar S., Zhu X., Pal D., and Mitra A.K. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 303 (2005) 8-19
15. Jain R., Duvvuri S., Kansara V., Mandava N.K., and Mitra A.K. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int. J. Pharm. 336 (2007) 233-240
16. Jain R., Majumdar S., Nashed Y., Pal D., and Mitra A.K. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol. Pharm. 1 (2004) 290-299
17. Jansen P.L., van Klinken J.W., van Gelder M., Ottenhoff R., and Elferink R.P. Preserved organic anion transport in mutant TR-rats with a hepatobiliary secretion defect. Am. J. Physiol. 265 (1993) G445-452
18. Katragadda S., Budda B., Anand B.S., and Mitra A.K. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin. Drug Deliv. 2 (2005) 683-705
19. Kim A.E., Dintaman J.M., Waddell D.S., and Silverman J.A. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286 (1998) 1439-1445
20. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
21. Lee C.G., and Gottesman M.M. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Invest. 101 (1998) 287-288
22. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., and Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37 (1998) 3594-3601
23. Lin J.H., Chen I.W., Vastag K.J., and Ostovic D. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23 (1995) 730-735
24. Lin J.H., Chiba M., Balani S.K., Chen I.W., Kwei G.Y., Vastag K.J., and Nishime J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24 (1996) 1111-1120
25. Morrow C.S., Smitherman P.K., and Townsend A.J. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol. Carcinog. 29 (2000) 170-178
26. Mottino A.D., Hoffman T., Jennes L., and Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. 293 (2000) 717-723
27. Park S., and Sinko P.J. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312 (2005) 1249-1256
28. Payen L., Sparfel L., Courtois A., Vernhet L., Guillouzo A., and Fardel O. The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol. Toxicol. 18 (2002) 221-233
29. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., and Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16 (1999) 1206-1212
30. Proust V., Toth K., Hulin A., Taburet A.M., Gimenez F., and Singlas E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 742 (2000) 453-458
31. Rambaut A., Posada D., Crandall K.A., and Holmes E.C. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5 (2004) 52-61
32. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3 (2006) 3-25
33. Rost D., Mahner S., Sugiyama Y., and Stremmel W. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G720-726
34. Schapiro J.M., Winters M.A., Stewart F., Efron B., Norris J., Kozal M.J., and Merigan T.C. The effect of high-dose saquinavir on viral load and CD4 + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124 (1996) 1039-1050
35. Su Y., Zhang X., and Sinko P.J. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm. 1 (2004) 49-56
36. Sudoh M., Pauletti G.M., Yao W., Moser W., Yokoyama A., Pasternak A., Sprengeler P.A., Smith III A.B., Hirschmann R., and Borchardt R.T. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers. Pharm. Res. 15 (1998) 719-725
37. Sutton S.C., Rinaldi M.T., and Vukovinsky K.E. Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci 3 (2001) E25
38. Ucpinar S.D., and Stavchansky S. Quantitative determination of saquinavir from Caco-2 cell monolayers by HPLC-UV. High performance liquid chromatography. Biomed. Chromatogr. 17 (2003) 21-25
39. Williams G.C., Liu A., Knipp G., and Sinko P.J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 46 (2002) 3456-3462
40. Williams G.C., and Sinko P.J. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39 (1999) 211-238
41. Wilson M.E., Allred K.F., Kordik E.M., Jasper D.K., Rosewell A.N., and Bisotti A.J. Gender-specific effects of HIV protease inhibitors on body mass in mice. AIDS Res. Ther. 4 (2007) 8
42. Wood E., Hogg R.S., Yip B., Moore D., Harrigan P.R., and Montaner J.S. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme. HIV Med. 8 (2007) 80-85